SmallCaps
ASX:RACPharmaceuticals, Biotechnology & Life SciencesBiotechnology

Racura Oncology Ltd

$2.140
+$0.020 (+0.94%)
Day Range
$2.130 – $2.180
52 Week Range
$1.130 – $4.900
Volume
60.63K
Avg Volume (10D)
144.72K
Market Cap
$419.59M
Price Chart
Market Statistics
Open$2.150
Previous Close$2.120
Day High$2.180
Day Low$2.130
52 Week High$4.900
52 Week Low$1.130
Valuation
Market Cap419.59M
Shares Outstanding196.07M
Price to Book16.88
Trading Activity
Volume60.63K
Value Traded130.36K
Bid$2.140 × 375
Ask$2.160 × 1,954
Performance
1 Day-4.76%
5 Day-0.90%
13 Week-13.39%
52 Week91.30%
YTD-19.41%
Technical Indicators
RSI (14)37.08
50-Day SMA$2.458
200-Day SMA$2.791
Latest News
Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial
Biotechnology

Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial

Racura Oncology starts Harness-1 Phase 1 with first patient dosed for RC220 + osimertinib in EGFR-mutant NSCLC; early safety data awaited.

By Imelda Cotton··1 min read min read
Racura Oncology Advances CPACS Trial to Next Dose Level
Biotechnology

Racura Oncology Advances CPACS Trial to Next Dose Level

Racura Oncology advances RC220 CPACS trial to 80mg/m2 as SRC clears Cohort 2; updated cardioprotection protocol; A$19.38m cash runway to CY2027.

By Isla Campbell··1 min read min read
Racura Oncology Advances Lung Cancer Program with HARNESS-1 Trial Approval
Biotechnology

Racura Oncology Advances Lung Cancer Program with HARNESS-1 Trial Approval

Racura Oncology wins HARNESS-1 Phase 1a/b governance approval for RC220/osimertinib in EGFR-mutant NSCLC, enabling site initiation and recruitment.

By Isla Campbell··1 min read min read
Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1)
Biotechnology

Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1)

Race Oncology (ASX: RAC) has discovered the primary anticancer mechanism of action for its lead drug candidate (E,E)-bisantrene, also known as RCDS1. New studies show the compound acts by binding to special DNA and RNA structures called G-quadruplexes, or G4s, which regulate many cancer-driving genes including the master switch MYC. Chief executive officer Dr Daniel Tillett […]

By Nik Hill··2 min read min read